Retatrutide significantly improved glycemic control and substantially reduced body weight in individuals with type 2 diabetes, with a safety profile aligned with that of GLP-1 receptor agonists and combined GIP and GLP-1 receptor agonists [108,109]. Here, GIP is linked to type 2 diabetes mellitus.